Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: A rationale to combine targeted drugs based on protein expression inhibition profiles

PHILIPPE G. AFTIMOS[1*], MURIELLE WIEDIG[2*], MIREILLE LANGOUO FONTSA[2], AHMAD AWADA[1], GHANEM GHANEM[2] and FABRICE JOURNE[2]

[1]Medical Oncology Clinic, [2]Laboratory of Oncology and Experimental Surgery, Jules Bordet Institute, Free University of Brussels, 1000 Brussels, Belgium

Received April 3, 2013; Accepted May 17, 2013

DOI: 10.3892/ijo.2013.2008

RETRACTED

Abstract. Targeted therapy has shown high efficacy in the treatment of metastatic melanoma with impressive response rates. However, resistance appears after a few months, underlining the need for simultaneous multiple signalling pathway inhibition to provide a durable benefit. The aim of our study was to evaluate the possible synergistic effect of various protein kinase inhibitor combinations targeting SRC, MEK, PI3K or JAK on the survival of representative melanoma cell lines with ^{WT}NRAS/^{WT}BRAF and harbouring the most frequent mutations (^{Q61L}NRAS/^{WT}BRAF or ^{WT}NRAS/^{V600E}BRAF). By comparing IC_{50}s and protein inhibition profiles, cell exposure to a single inhibitor for 3 days (condition 1) showed that both ^{WT}BRAF lines were at least 15-fold more sensitive to SRC inhibition while ^{V600E}BRAF cells were 30-fold more sensitive to MEK inhibition, confirming that the latter cells are largely dependent on the MAPK pathway for growth. Concomitant treatment for 3 days (condition 2) revealed an antagonistic effect between SRC and JAK inhibitors as compared to treatment by each inhibitor alone in all 3 lines, supporting that both SRC and JAK stimulate the STAT pathway. Finally, sequential cell exposure to inhibitors by pre-treatment with a single effector at non-toxic but effective on target inhibition concentrations for 7 days followed by the addition of each of the other inhibitors for 3 days (condition 3) showed that MEK, PI3K or JAK inhibitor acted in synergy with the SRC inhibitor in both wild-type and ^{Q61L}NRAS cells, suggesting that the first inhibitor could activate the SRC/STAT compensatory signalling pathway. In conclusion, a treatment strategy consisting in a sequential use of targeted inhibitors to first render melanoma cells more dependent on alternative compensatory pathways that should subsequently be inhibited, may enhance efficacy. By contrast, concomitant exposure to various combinations of inhibitors at different concentrations failed to produce such effect, further supporting the importance of both the duration of cell exposure to inhibitors and their sequential use.

Correspondence to: Dr Fabrice Journe, Institut Jules Bordet, Free University of Brussels, 1 rue Heger-Bordet, 1000 Brussels, Belgium
E-mail: fabrice.journe@bordet.be

*Contributed equally

Key words: melanoma cell lines, signalling pathway, mutation, protein kinase inhibitor, cell proliferation

Introduction

Cutaneous melanoma is a tumor arising from epidermal melanocytes. It particularly affects young patients as it is the third most frequent cancer in the age range of 20-39 years (1). Although melanoma accounts for only 4% of all skin cancers, it is responsible for 80% of deaths (2). The survival rate at 10 years for patients with metastatic melanoma is <10% (2). During the two last decades, the incidence of melanoma as well as the associated-mortality have strongly increased (3), transforming this disease into a real public health problem.

With the increase in public awareness campaigns, the diagnosis of melanoma is being diagnosed at an earlier stage when the disease is still curable by surgery. At this stage, the survival rate at 5 years is 90% (4). On the other hand, metastatic melanoma is an incurable disease. Multimodality treatments are necessary. Historically, chemotherapy (dacarbazine, cisplatin) and immunotherapy (interferon α-2b and interleukin-2) were for a long time the mainstay of treatment. Dacarbazine was the only FDA approved cytotoxic agent even though it produced low response rates. Interferon and interleukin have showed impressive antitumoral activity with a number of complete responses but in a very small subset of patients. The landscape of the treatment of metastatic melanoma has changed recently with the emergence of new immuno-modulatory agents such as anti-CTLA-4, anti-PD1, anti-PD-L1 monoclonal antibodies (5,6) and pathway inhibitors such as BRAF and MEK inhibitors (7-9).

The description of activating BRAF gene mutations in 50-60% of melanomas (10) opened a new therapeutic perspective. Indeed, treatment with the specific ^{V600E}BRAF inhibitor vemurafenib resulted in spectacular tumor regressions (11), improved rates of overall and progression-free survival

compared to dacarbazine (12) and induced clinical response in >50% of metastatic melanoma patients harbouring the BRAF mutation (median overall survival was ~16 months) (7). Nevertheless, in spite of impressive initial responses, selection and/or resistance developed in many cases due to exogenous growth factors and cytokines (13), switches between pathways (14), COT/MAP3K8 activation (15), appearance of new activation mutations in C121SMEK1 (16), dimerization of aberrantly spliced ^{V600E}BRAF (17) or prevalence of wild-type cells in the tumors (18).

Besides BRAF, several other mutated or upregulated proteins involved in major signalling pathways may be considered as additional potential targets in cutaneous melanoma. First, the RAS/RAF/MEK/ERK signalling pathway is a major target for therapy as it is hyper-activated in ~75% of metastatic tumors. Indeed, NRAS activated mutations are found in 15-25% of cases with the remaining being BRAF mutated, both mutations being mutually exclusive (10). Second, PI3K/AKT/mTOR signalling is another important pathway in melanoma because of its activation through the loss of the expression of the tumor suppressor PTEN (30-50%) or the amplification of AKT (60%) (19). Interestingly, genetic interaction between NRAS and BRAF mutations and PTEN inactivation has been reported, (20) suggesting possible cooperation between both MAPK and PI3K/AKT activations in melanoma development (21). Finally, STAT3 is a point of convergence for many tyrosine kinases such as JAK and SRC. It is constitutively activated in a majority of human melanoma cell lines and tumors where it plays a key role in growth and survival (22). Moreover, its activation has been reported as a compensatory mechanism allowing cell survival and contributing to resistance to targeted drugs such as SRC inhibitors (23).

In light of the recent data on targeted therapy and keeping in mind the identified crosstalk between different signalling pathways in melanoma, it was evident that more effective treatments need concomitant inhibition of multiple pathways. The choice and modalities of such combinations are currently investigated both in *in vitro* models and in clinical trials. Our working hypothesis is based on a particular approach by which a sustained inhibition of a given signalling pathway renders cells dependent on other compensatory pathways for their proliferation and survival. The identification and subsequent targeting of the latter as well could substantially potentiate cell toxicity. Hence, we induced changes in signalling profiles in three representative melanoma cell lines (wild-type or mutated in NRAS or BRAF) by using a sequential exposure first to non-toxic (<10% toxicity) but effective (substantial inhibition of targeted kinase) concentrations of various protein kinase inhibitors targeting MEK, PI3K, SRC or JAK and second, while maintaining these inhibitions, to adequate protein kinase inhibitors targeting the activated compensatory signalling pathways. The results have been systematically compared to each effector used alone or in simultaneous combination with the others.

Materials and methods

Inhibitors. Four specific inhibitors of protein kinases has been used: the SRC family inhibitor PP2 (IC_{50} = ~5 nM, 50% of kinase activity inhibition), the MEK1/2 inhibitor U0126 (IC_{50} = ~0.1 μM), the PI3K inhibitor LY294002 referred as LY29 (IC_{50} = ~1 μM) (all from Tocris Bioscience, Bristol, UK) and the JAK Inhibitor I pyridone 6 referred as PYR (IC_{50} = ~5 nM) (Calbiochem, Darmstadt, Germany).

Melanoma cell lines. Human melanoma cell lines were established in our laboratory from lymph node metastases. HBL cells (LOCE-MM001) are wild-type for NRAS and BRAF, LOCE-MM057 present the Q61L NRAS mutation and LOCE-MM074 are bearing the V600E BRAF mutation.

Cell culture. Cells were cultured at 37˚C in a humidified 95% air and 5% carbon dioxide atmosphere. For routine maintenance, cells were propagated in 175 cm^2-flasks containing HAM-F10 medium supplemented with 5% heat-inactivated fetal calf serum and 5% heat-inactivated newborn calf serum and with L-glutamine, penicillin and streptomycin at standard concentrations (all from Gibco, Invitrogen, UK). Cells were harvested by trypsinization (0.05% trypsin - EDTA) (Gibco) and subcultured twice weekly. One day after seeding, the culture medium was replaced by fresh medium. All lines are routinely checked for mycoplasma contamination using MycoAlert™ Mycoplasma Detection kit (Lonza, Basel, Switzerland).

Experimental conditions. Experimental conditions are presented in Fig. 1 as follows: condition 1 (cell exposure to one single inhibitor), cells were exposed to increasing concentrations (from 10^{-12} to 10^{-4} M) of each of the protein kinase inhibitors for 3 days; condition 2 (concomitant exposure to two inhibitors), cells were incubated with a given concentration of an inhibitor and co-treated with increasing concentrations of another for 3 days; condition 3 (sequential exposure), cells were exposed to each of the inhibitors for 7 days (medium and inhibitor renewal at days 1, 4 and 7) and, while maintaining this pre-treatment, cells were incubated for 3 additional days with increasing concentrations of each of the other inhibitors.

Proliferation assay. All cells were seeded in 96-well plates (8,000 cells/well) containing HAM-F10 medium supplemented or not with inhibitors. One day after plating, the culture medium was replaced by a fresh one containing inhibitors depending on experimental conditions (Fig. 1) and further cultured for 3 additional days. Cell proliferation was assessed by crystal violet assay. Briefly, culture medium was removed and cells were gently rinsed with phosphate-buffered saline (PBS), fixed with 1% glutaraldehyde/PBS for 15 min and stained with 0.1% (w/v in water) crystal violet for 30 min. Cells were destained under running tap water and subsequently lysed with 0.2% (v/v in water) Triton X-100 for 90 min. The absorbance was measured at 570 nm using a Multiskan EX Microplate Photometer (Thermo Scientific, Courtaboeuf Cedex, France). On each plate, blank wells containing medium alone were used for background subtraction and untreated (control) cells were cultured in parallel to treated cells.

Western blot analysis. Expression and/or phosphorylation levels of key proteins of targeted signalling pathways were determined by western blotting in untreated cells and cells exposed to inhibitors for 30 min or 10 days. All cells were

RETRACTED



Figure 1. Workflow presenting the three experimental conditions used for protein kinase inhibitor combinations.

RETRACTED

plated in Petri dishes ($3x10^6$ cells/dish) containing HAM-F10 medium and cultured according to the experimental conditions outlined in Fig. 1. Cells were then lysed using detergent cocktail (M-PER mammalian extraction buffer) supplemented with protease inhibitors (Halt protease inhibitor cocktail) and phosphatase inhibitors (Halt phosphatase inhibitor cocktail) (all from Pierce, Rockford, IL, USA). Protein concentrations were determined by the BCA protein assay (Pierce) using bovine serum albumin as a standard. Equal amounts of cell proteins (30 μg) were subjected to 10% SDS-PAGE and electrotransferred onto nitrocellulose membranes using iBlot® Dry Blotting System (Invitrogen, Life Technologies, Gent, Belgium). Immunodetection was performed using antibodies raised against pSRC (Tyr 416) (1/1,000), SRC (1/1,000), pAKT (Ser 473) (D9E, 1/500), AKT (40D4, 1/2,000), PTEN (138G6, 1/1,000), pSTAT3 (Tyr 705) (D3A7, 1/1,000) (all from Cell Signaling Technology, Danvers, MA, USA) and pERK (Tyr 204) (E-4, 1/1,000), ERK2 (C-14, 1/2,000), STAT3 (K-15, 1/200) (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA). Peroxidase-labeled anti-rabbit IgG antibody (1/5,000) or peroxidase-labeled anti-mouse IgG antibody (1/5,000) (both from Amersham Pharmacia Biotech) were used as secondary reagents to detect corresponding primary antibodies. Bound peroxidase activity was revealed using the SuperSignal® West Pico Chemiluminescent Substrate (Pierce). Immunostaining signals were digitalized with a PC-driven LAS-3000 CCD camera (Fujifilm, Tokyo, Japan), using a software specifically designed for image acquisition (Image Reader, Raytest®, Straubenhardt, Germany).

Statistical analysis. IC_{10} and IC_{50} values were calculated using GraphPad Prism software (GraphPad Software, La Jolla, CA, USA). Data are reported as means ± SEM and significance was calculated by Student's t-test using SPSS software (SPSS Inc., Paris, France). $^{*}p<0.05$, $^{**}p<0.01$, $^{***}p<0.001$.

Results

Characteristics of the representative melanoma cell lines relevant for the study. HBL cells are wild-type for NRAS and BRAF, MM057 cells present the Q61L mutation in NRAS and MM074 cells bear the V600E mutation in BRAF. Analysis of constitutive levels of phosphorylation/expression of key proteins involved in the master signalling pathways (SRC, MAPK, PI3K/AKT, JAK/STAT) in melanoma cells showed that HBL cells exhibit low phosphorylation of ERK and high phosphorylation of AKT, MM057 cells have high phosphorylation of both ERK and AKT, while MM074 cells show high phosphorylation of ERK but low phosphorylation of AKT (Fig. 2A). PTEN expression is not different among lines. Interestingly, we observed an inverse relation between the phosphorylations of SRC and STAT3, with high SRC phosphorylation in HBL and MM074 cells and high STAT3 phosphorylation in MM057 cells. Of note, these phosphorylation profiles of MM057 and MM074 cells are compatible with the mutational status of NRAS and BRAF, respectively.

On the other hand, we examined the proliferation rate of each cell line (day-3/day-1 ratio, crystal violet assay) and found that HBL cells were highly proliferative, MM057 cells were moderately, while MM074 cells had the lowest proliferation rate (2-fold less compared to HBL), suggesting that activating mutations in NRAS or BRAF are not necessarily associated with a higher proliferation rate (Fig. 2B) as also suggested by others (22).

Cell exposure to each inhibitor alone (condition 1). We evaluated the anti-proliferative effect of each inhibitor in all cell lines after 3 days of treatment (condition 1, see Materials and methods) (Fig. 3) and we determined the IC_{10} and IC_{50} in all cases (Table I). We found that wild-type BRAF cells (HBL, MM057) were more sensitive to the SRC inhibitor PP2 than



Figure 2. (A) Constitutive phosphorylation and expression levels of SRC, ERK, AKT, PTEN and STAT3 proteins (β-actin as loading control, western blot analysis). (B) Proliferation rates in melanoma cell lines expressed as day-3/day-1 ratios (crystal violet assay). Data show mean values ± SEM of 3 experiments.



Figure 3. Effect of 3 days of treatment with inhibitors on cell proliferation (condition 1). Cells were incubated with increasing concentrations (10^{-12}-10^{-4} M) of inhibitors and cell growth was evaluated by crystal violet assay. Data represent the mean values ± SEM of 3 experiments.

Table I. IC_{10} and IC_{50} determination (μM) for HBL (^{WT}NRAS/^{WT}BRAF), MM057 (^{Q61L}NRAS) and MM074 (^{V600E}BRAF) exposed to SRC (PP2), MEK (U0126), PI3K (LY29) and JAK (PYR) inhibitors for 3 days (condition 1).

	HBL		MM057		MM074	
Inhibitors	IC_{10}	IC_{50}	IC_{10}	IC_{50}	IC_{10}	IC_{50}
PP2	0.003	0.2	0.01	0.1	0.02	3
U0126	<0.001	100	0.5	30	0.02	0.7
LY29	10	100	2	30	5	100
PYR	0.02	0.5	0.1	2	<0.001	0.06

^{V600E}BRAF cells (MM074), whereas HBL and MM057 cells had a lower level of phosphorylation of SRC than MM074 cells (Fig. 2A). As expected, the ^{V600E}BRAF cells were much more responding to the MEK inhibitor U0126 than the wild-type BRAF ones (especially HBL cells), in agreement with the hyper-activation of the MAPK signalling pathway in the former cells. The PI3K inhibitor LY29 had comparable weak inhibitory effects in the 3 cell lines, while the PI3K/AKT signalling pathway appeared weakly activated in MM074 cells. Finally, the JAK inhibitor PYR was the less effective in the ^{Q61L}NRAS cells (MM057) which are the only ones to exhibit an activation of STAT3. Thus, because of probable activation of alternative signalling pathways in cells under treatments, inhibitors were not necessary more effective in lines exhibiting higher activation of their targeted pathways.

Concomitant cell exposure to two inhibitors (condition 2). Based on the effect of each inhibitor in all lines (Table I), we selected the highest non-toxic concentrations (0.05 μM PP2, 0.5 μM U0126, 5 μM LY29 and 0.05 μM PYR) after one

RETRACTED



Figure 4. Effect of inhibitors on targeted pathways by evaluating phosphorylation and expression of SRC, ERK, AKT and STAT3 proteins after 30 min of treatment (western blot analyses).



Figure 5. Assessment of proliferation rates after 10 days of exposure to fixed concentrations of inhibitors. Proliferation rates are expressed as day-3/day-1 ratios (crystal violet assay). Data show mean values ± SEM of 3 experiments.

week exposure to be subsequently used for inhibitor combination experiments (condition 2, see Materials and methods). Importantly, using western blot analysis, they were effective in inhibiting targeted signalling pathways after 30-min exposure (Fig. 4). Indeed, PP2 inhibited SRC phosphorylation in both HBL and MM074 cells, U0126 affected ERK phosphorylation in all cell lines, LY29 interfered with AKT phosphorylation in HBL and MM057 lines and PYR decreased STAT3 phosphorylation in MM057 cells.

Sequential cell exposure to inhibitors (condition 3). We first examined the anti-proliferative effect of each inhibitor alone at the above mentioned non-toxic concentrations after 10 days of continuous exposure. As documented in Fig. 5, we found that all cell lines were not or were only weakly affected by long-term treatment with each inhibitor (proliferation rate >1), except in the ^{V600E}BRAF cells (MM074) where 0.5 μM U0126 is highly toxic (proliferation rate ~0.4).

Then, we evaluated whether pre-treatment with a first inhibitor potentiated the anti-proliferative effect of a second inhibitor (condition 3), as compared to simultaneous treatment with both inhibitors (condition 2) and the effect of the second inhibitor alone (condition 1). By comparing IC_{50}s, we found that pre-treatment (condition 3) with MEK, PI3K or JAK inhibitors showed synergistic effects when specimens were subsequently exposed to an SRC inhibitor (Table II, in italics) in both HBL and MM057 cell lines. These effects may be explained by the fact that pre-treatment with U0126, LY29 or PYR increased SRC expression/phosphorylation in these lines (Fig. 6). In addition, we also observed synergy between PP2 or U0126 pre-treatment and then exposure to

RETRACTED

Table II. IC_{50} determination (μM) for HBL, MM057 and MM074 exposed to concomitant (condition 2) or sequential (condition 3) combinations of SRC (PP2), MEK (U0126), PI3K (LY29) and JAK (PYR) inhibitors for 3 days.

Inhibitors		HBL		MM057		MM074	
1 Fixed conc.	2 Increasing conc.	Concomitant exposure IC_{50} (μM)	Sequential exposure IC_{50} (μM)	Concomitant exposure IC_{50} (μM)	Sequential exposure IC_{50} (μM)	Concomitant exposure IC_{50} (μM)	Sequential exposure IC_{50} (μM)
PP2	U0126	>100	>100	50	20	50	50
0.05 μM	LY29	30	2	50	20	30	10
	PYR	**50**[a]	**0.002**[a]	>100	50	50	5
U0126	PP2	*4*[a]	*0.02*[a]	*>100*[a]	*0.5*[a]	>100	>100
0.50 μM	LY29	10	5	>100	50	50[a]	<0.001[a]
	PYR	**20**[a]	**<0.001**[a]	20	50	**30**[a]	**<0.001**[a]
LY29	PP2	*0.1*[a]	*<0.001*[a]	*1*[a]	*<0.001*[a]	>100	>100
5.00 μM	U0126	10	0.1	3	5	5	30
	PYR	1	0.1	30	10	5	>100
PYR	PP2	*70*[a]	*0.5*[a]	*20*[a]	*0.03*[a]	>100	5
0.05 μM	U0126	2	50	>10	50	10	50
	LY29	2	50	2	50	50	50

[a]At least 100-fold decrease of IC_{50} in sequential vs concomitant exposure.

RETRACTED



Figure 6. Effect of 10-day cell exposure to inhibitors on phosphorylation and expression of SRC and AKT (western blot analysis).

PYR in HBL cells and between U0126 pre-treatment and PYR in MM074 cells (Table II, in bold). However, STAT3 was not necessary more phosphorylated after these pre-treatments, suggesting that other JAK downstream targets should have been activated. Furthermore, sequential exposure to U0126 and then LY29 showed synergy in inhibiting MM074 cell proliferation (Table II, underlined), in the line with the AKT higher phosphorylation due to the pre-treatment with a MEK inhibitor (Fig. 6). By contrast, some concomitant treatments (condition 2) resulted in antagonistic effects when SRC and JAK inhibitors are combined (Table II), as compared to each inhibitor alone in all three cell lines (Table I).

Discussion

Conventional chemotherapy with dacarbazine, approved by the FDA (Food Drugs Administration) in 1975, was the standard for treatment of melanoma patients until recently (24). Overall response rate is 15% (mostly partial responses) but with no evidence of survival benefit. Immunotherapy with high-dose interleukin-2 or interferon α-2b have been associated with relatively durable responses but only in a small subset of patients, with yet no factors predicting which patients will respond to this therapy (25). Although they showed limited efficacy, these various therapies allowed considerable progress in the understanding of melanoma biology and molecular mechanisms involved in melanomagenesis.

Recent advances in cell biology and the design of targeted therapies led to unprecedented response rates with the new targeted agents. A strategy aiming at restoring the immune

system response to disease has been developed, in particular, with ipilumumab, an antibody raised against CTLA-4 (cytotoxic T-lymphocyte antigen 4), a protein receptor responsible for immune tolerance. It improved overall survival in patients within a trial randomizing patients with previously treated metastatic melanoma into 3 treatment arms. Moreover, 9 of 15 responders (60%) in the ipilimumab only group maintained an objective response for ≥2 years (5). Ipilimumab in combination with dacarbazine improved overall survival versus dacarbazine plus placebo in patients with previously untreated metastatic melanoma (26). A similar immune strategy with an anti-PD1 or anti-PD-L1 (programmed death 1, ligand) antibody produced objective responses in ~28% of patients with melanoma. Interestingly, preliminary data suggest a relationship between PD-L1 expression on tumor cells and objective responses (6).

Furthermore, recent clinical data provided a strong indication for the efficacy of single agent targeted therapy approaches in melanoma. First, vemurafenib has been reported to induce clinical responses in >50% of metastatic melanoma patients bearing ^{V600E}BRAF mutated tumors (7). Then, dabrafenib, another ^{V600E}BRAF inhibitor, produced promising tumor shrinkage in patients with brain metastases, a frequent complication of metastatic melanoma (8). Lastly, trametinib, a selective inhibitor of MEK1 and MEK2, downstream effectors within the MAP kinase pathway, improved progression-free survival and overall survival as compared to chemotherapy in metastatic melanoma patients with BRAF V600E/K mutations (9). Importantly, the combination of dabrafenib and trametinib had an acceptable safety profile with a lower incidence of MEK inhibitor-related rash and BRAF inhibitor-induced hyper-proliferative skin lesions compared to the single agents (27). Unfortunately, the impressive response rates with these agents are short-lived, prompting the research for combinatorial strategies and the discovery of research mechanisms. A discontinuous dosing regimen with vemurafenib could emerge as a strategy to overcome resistance because vemurafenib-resistant melanomas become drug-dependent for their continued proliferation (28). Although many studies both *in vitro* and in clinical trials have been devoted to search for the best targeted drug combinations, encouraging but modest results have been recorded most probably due to the heterogeneous biological behaviour of melanoma tumor cells. In a recent study, pairwise combinations of an array of small-molecule inhibitors on early-passage melanoma cultures using combinatorial drug screening revealed several inhibitor combinations effective for melanoma treatment (29). Such investigations have to be continued in order to identify the most effective inhibitor combinations. In our study, we aimed to design an alternative rationale to combine targeted drugs to potentiate anti-proliferative effect of protein kinase inhibitors in order to overcome one of the major resistance mechanism to such drugs in melanoma. We selected 3 representative cell lines based on their MAPK mutation status: ^{V600E}BRAF cells (MM074), ^{Q61L}NRAS cells (MM057) and wild-type cells (HBL). Of note, inverse correlations were observed between ERK phosphorylation and AKT phosphorylation in wild-type HBL cells and ^{V600E}BRAF MM074 cells, confirming crosstalk between MAPK and PI3K/AKT pathways (21), while ERK and AKT were highly phosphorylated in the ^{Q61L}NRAS MM057 cells, because NRAS is upstream of both signalling pathways. Previous studies reported that the consequence of a constitutive MAPK activation in melanoma includes the increase in cell proliferation and invasion (30) and that, whereas ^{V600E}BRAF stimulated cell proliferation in melanoma, it induced senescence in melanocytes (31-34). However, and in agreement with others (35), we observed that the ^{V600E}BRAF mutation was associated with significantly lower proliferation rates in many cell lines that we have examined up-to-now (data not shown) and in particular is true for MM074 cells used in the present study. Of note, we confirmed that the BRAF mutation makes cancer cells more dependent on the MAPK pathway for their survival (36).

We also examined if the phosphorylation level of key kinases (SRC, ERK, AKT, STAT3) could be predictive of the response to protein kinase inhibitors regarding cell proliferation. We found that: (I) although both wild-type (HBL) and ^{V600E}BRAF (MM074) cells exhibited a high phosphorylation level of SRC, the wild-type cells were 15-fold more sensitive to an SRC inhibitor, (II) while ^{Q61L}NRAS (MM057) and ^{V600E}BRAF (MM074) cells have a high phosphorylation level of ERK, ^{V600E}BRAF cells were 30-fold more sensitive to a MEK inhibitor, (III) whereas wild-type (HBL) and ^{Q61L}NRAS (MM057) cells showed higher AKT phosphorylation levels than ^{V600E}BRAF (MM074) cells, all cells had similar sensitivity to PI3K inhibitor and (IV) although ^{Q61L}NRAS cells are the only ones to exhibit STAT3 phosphorylation, they were the least sensitive to a JAK inhibitor. Altogether, our data indicate that even if the phosphorylation level of key kinases correlates with the activation of the corresponding signalling pathway, it cannot be used alone, as a marker to predict the response to corresponding up-stream specific inhibitors because similar level of phosphorylation could be caused by various alternative mechanisms present in a given cell line, mainly related to exogenous growth factors and cytokines stimulations, mutation status, or crosstalk between signalling pathways. For example, ERK phosphorylation may be induced by growth factor stimulation, RAS or SRC activation, BRAF mutation and AKT-mediated phosphatase inhibition.

Many studies have reported the efficacy of multiple targeted therapies against cancer (37,38) and suggested a benefit of simultaneous inhibitions of different signalling pathways (39). However, little attention has been paid to sequential treatment that might be more relevant to clinical situation. Our hypothesis was that a long-term inhibition of a given signalling pathway renders melanoma cells dependent on other compensatory pathways for their proliferation and survival that can be different among subgroups of tumors. This information is crucial to subsequently target the correct pathway to possibly potentiate the effect (24). Accordingly, we found that a 10-day cell exposure to a protein kinase inhibitor affected the signalling pathway profiles as documented by western blot analyses of the phosphorylation levels of the master signalling proteins. For example, in wild-type HBL and ^{Q61L}NRAS MM057 cell lines, MEK, PI3K and JAK inhibitors stimulated the phosphorylation of SRC, rendering both lines more sensitive to SRC inhibition. Moreover, in ^{V600E}BRAF MM074, MEK inhibitor increased the phosphorylation of AKT leading to cells more responsive to AKT inhibition. Thus, we found that long-term cell exposure to a specific protein kinase inhibitor may enhance

RETRACTED

the anti-proliferative effect of another protein kinase inhibitor, supporting that melanoma cells became dependent on an alternative pathway for survival after a pre-treatment (40). Most interesting is the fact that these pre-treatments were done at non-toxic but kinase inhibition effective concentrations. By contrast, simultaneous use of inhibitors may surprisingly yield antagonistic effects. Indeed, this was observed with a concomitant exposure to SRC and JAK inhibitors, both proteins can affect the STAT pathway (41).

In conclusion, the present study adds new insight into drug combination strategies by focusing on a sequential use of kinase targeted inhibitors and on long-term priming/sensitizing tumor cells with a first effector used at non-toxic but effective concentrations to potentiate the effect of a second inhibitor. Our data strongly support a strategy based on the identification of both mutation status and signalling pathway profiles of a given tumor to select melanoma patients and propose adequate drug combinations and most importantly sequential administration schedules.

Acknowledgements

This study received financial support from 'MEDIC Foundation', 'Les Amis de l'Institut Bordet' and 'Fondation Lambeau-Marteaux'.

References

1. Rokuhara S, Saida T, Oguchi M, Matsumoto K, Murase S and Oguchi S: Number of acquired melanocytic nevi in patients with melanoma and control subjects in Japan: Nevus count is a significant risk factor for nonacral melanoma but not for acral melanoma. J Am Acad Dermatol 50: 695-700, 2004.
2. Miller AJ and Mihm MC Jr: Melanoma. N Engl J Med 355: 51-65, 2006.
3. Berwick M, Erdei E and Hay J: Melanoma epidemiology and public health. Dermatol Clin 27: 205-214, viii, 2009.
4. Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL and Chanmugam A: Cutaneous malignant melanoma. Mayo Clin Proc 81: 500-507, 2006.
5. Hodi FS, O'Day SJ, McDermott DF, *et al*: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723, 2010.
6. Topalian SL, Hodi FS, Brahmer JR, *et al*: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454, 2012.
7. Sosman JA, Kim KB, Schuchter L, *et al*: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366: 707-714, 2012.
8. Falchook GS, Long GV, Kurzrock R, *et al*: Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379: 1893-1901, 2012.
9. Flaherty KT, Robert C, Hersey P, *et al*: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367: 107-114, 2012.
10. Davies H, Bignell GR, Cox C, *et al*: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002.
11. Flaherty KT, Puzanov I, Kim KB, *et al*: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819, 2010.
12. Chapman PB, Hauschild A, Robert C, *et al*: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011.
13. Christensen C and Guldberg P: Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF. Oncogene 24: 6292-6302, 2005.
14. Montagut C, Sharma SV, Shioda T, *et al*: Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 68: 4853-4861, 2008.
15. Johannessen CM, Boehm JS, Kim SY, *et al*: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468: 968-972, 2010.
16. Wagle N, Emery C, Berger MF, *et al*: Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29: 3085-3096, 2011.
17. Poulikakos PI, Persaud Y, Janakiraman M, *et al*: RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480: 387-390, 2011.
18. Yancovitz M, Litterman A, Yoon J, *et al*: Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma. PLoS One 7: e29336, 2012.
19. Tsao H, Zhang X, Benoit E and Haluska FG: Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 16: 3397-3402, 1998.
20. Tsao H, Goel V, Wu H, Yang G and Haluska FG: Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 122: 337-341, 2004.
21. Cheung M, Sharma A, Madhunapantula SV and Robertson GP: Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res 68: 3429-3439, 2008.
22. Niu G, Bowman T, Huang M, *et al*: Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21: 7001-7010, 2002.
23. Byers LA, Sen B, Saigal B, *et al*: Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res 15: 6852-6861, 2009.
24. Ji Z, Flaherty KT and Tsao H: Molecular therapeutic approaches to melanoma. Mol Aspects Med 31: 194-204, 2010.
25. Yurkovetsky ZR, Kirkwood JM, Edington HD, *et al*: Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 13: 2422-2428, 2007.
26. Robert C, Thomas L, Bondarenko I, *et al*: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526, 2011.
27. Flaherty KT, Infante JR, Daud A, *et al*: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367: 1694-1703, 2012.
28. Das Thakur M, Salangsang F, Landman AS, *et al*: Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494: 251-255, 2013.
29. Held MA, Langdon CG, Platt JT, *et al*: Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov 3: 52-67, 2013.
30. Smalley KS: A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 104: 527-532, 2003.
31. Garnett MJ and Marais R: Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6: 313-319, 2004.
32. Gray-Schopfer VC, Cheong SC, Chong H, *et al*: Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer 95: 496-505, 2006.
33. Michaloglou C, Vredeveld LC, Soengas MS, *et al*: BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436: 720-724, 2005.
34. Pollock PM, Harper UL, Hansen KS, *et al*: High frequency of BRAF mutations in nevi. Nat Genet 33: 19-20, 2003.
35. Dhomen N, Reis-Filho JS, da Rocha Dias S, *et al*: Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15: 294-303, 2009.
36. Wellbrock C, Karasarides M and Marais R: The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5: 875-885, 2004.
37. Gopal YN, Deng W, Woodman SE, *et al*: Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 70: 8736-8747, 2010.
38. Solit DB and Rosen N: Resistance to BRAF inhibition in melanomas. N Engl J Med 364: 772-774, 2011.
39. Villanueva J, Vultur A, Lee JT, *et al*: Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18: 683-695, 2010.
40. Flaherty KT and Smalley KS: Preclinical and clinical development of targeted therapy in melanoma: attention to schedule. Pigment Cell Melanoma Res 22: 529-531, 2009.
41. Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle PK and Einarson TR: Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev 33: 665-680, 2007.

RETRACTED